Stroke is a leading cause of mortality and disability worldwide [1] and approximately 20 to 25% of ischemic stroke are anticipated by transient ischemic symptoms [2]. The risk of ischemic stroke ranges from 3 to 15% in the 90 days after a transient ischemic attack (TIA) or a minor ischemic stroke [3,4]. Aspirin is known to reduce the risk of recurrent stroke by approximately 20% [5,6] and it is currently considered the antithrombotic drug of choice in non-cardioembolic stroke patients [7]. Indeed, in patients with non-cardioembolic ischemic stroke, aspirin is the most effective treatment to reduce the risk of stroke recurrence during the first 3 months, and it is the only antiplatelet drug that has shown to reduce the risk of recurrent disabling ischemic stroke [8].
